CareTrust REIT, Inc. (CTRE) Stock Price & How to Invest

CareTrust REIT owns healthcare real estate and does not operate any of it. The portfolio is mostly skilled nursing facilities, with a growing share of senior housing, assisted living and multi-service campuses, spread across roughly 30 US states and, since the 2025 acquisition of UK-listed Care REIT plc, the United Kingdom. Properties are leased to regional and national operators under triple-net structures, meaning the tenant pays taxes, insurance and maintenance and CareTrust collects contractual rent with annual escalators. The company was spun off from The Ensign Group in 2014, which is why Ensign remains its largest tenant, and it has since diversified into a roster where the top ten operators account for roughly 69% of rent. Alongside owned real estate it runs a mortgage and mezzanine loan book, which functions as a pipeline into future acquisitions.

The investment picture in August 2026 is a growth REIT rather than a yield REIT. Second-quarter revenue of ~$161 million was up sharply from ~$113 million a year earlier, normalized FFO per share of ~$0.51 rose ~19%, and management raised full-year normalized FFO guidance to ~$2.03 to $2.06 per share, roughly 16% growth at the midpoint. That growth is bought: CareTrust deployed ~$1.5 billion year to date at a blended stabilized yield near 8.7%, funded largely with equity, which is why net debt sits around 1.0x annualized normalized run-rate EBITDA, an unusually light balance sheet for a REIT. At a ~$39 share price and ~$9.3 billion market capitalization the stock trades near 19x guided 2026 normalized FFO with a ~4% dividend yield covered at about 76% of normalized FAD. The trade-off is concentration and policy: Ensign is ~21% of annualized rent, PACS Group is ~10% and has been dealing with a federal investigation and shareholder litigation of its own, and nearly all operator revenue ultimately traces back to Medicare and Medicaid.

Tenant concentration is the sharpest risk: Ensign accounts for ~21% of annualized rent and PACS Group ~10%, and PACS has been contending with a federal investigation into its reimbursement and referral practices plus shareholder litigation, so a single operator's trouble can travel straight into CareTrust's rent roll. Reimbursement policy sits underneath everything, since operators are paid mostly by Medicare and Medicaid, and the 2025 federal law steps the state provider tax cap down from 6% to 3.5% by fiscal 2032 in Medicaid expansion states while individual states debate their own rate cuts. The growth model itself is a dependency: mid-teens FFO per share growth requires continuously issuing equity and finding deals at 8%-plus yields, and if either the equity window closes or cap rates compress, the growth rate resets to escalators alone. Interest rates cut both ways, raising the cost of the debt CareTrust has not yet drawn and setting the yield investors demand on the stock. The UK portfolio adds currency exposure, with guidance explicitly assuming no material move in the GBP to USD rate.

13 analysts publish price targets on CTRE, averaging $45.38 against a $39.16 price as of August 2026, or +15.9%. The published targets run from $43.00 to $49.00, a narrow spread, and the ratings split 13 buy, 0 hold, 0 sell. Over the last six months there have been 5 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CTRE forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on CareTrust REIT, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Acquisitions at a wide spread over cost of capital. CareTrust closed ~$900 million of investments in the second quarter at a ~8.9% blended stabilized yield, its largest non-M&A quarter, plus ~$308 million after quarter end at ~7.8%, taking year-to-date deployment to ~$1.5 billion at ~8.7%. The most optimistic published target, $49.00, assumes this works close to its best case.

The case against. Tenant concentration is the sharpest risk: Ensign accounts for ~21% of annualized rent and PACS Group ~10%, and PACS has been contending with a federal investigation into its reimbursement and referral practices plus shareholder litigation, so a single operator's trouble can travel straight into CareTrust's rent roll. The most pessimistic target, $43.00, is roughly what CTRE is worth if this bites instead.

Read the full bull and bear case on CTRE, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see CareTrust REIT, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$571 million, with Q2 2026 at ~$161 million versus ~$113 million a year earlier
• Normalized FFO per share (Q2 2026): ~$0.51, up ~19% year over year
• FY2026 normalized FFO per share guidance: ~$2.03 to $2.06, about 16% growth at the midpoint
• Dividend: ~$0.39 per quarter, ~$1.56 annualized, roughly a 4% yield and ~76% of normalized FAD
• Price to 2026 normalized FFO: ~19x at a ~$39 share price and ~$9.3 billion market cap
• Net debt to annualized normalized run-rate EBITDA: ~1.0x, down from ~2.0x a year earlier

Net income of ~$89 million (~$0.38 per diluted share) in the second quarter understates the cash the business generates, because REIT accounting charges large non-cash depreciation against buildings that are not actually losing value, which is why guidance and the dividend are both framed against normalized FFO and FAD. The multiple of ~19x guided FFO is above most skilled nursing landlords and below the diversified large-cap healthcare REITs, which is roughly where a small-cap REIT growing per-share cash flow in the mid teens with almost no leverage tends to sit. The number that would move that multiple most is not the growth rate but rent coverage at the top operators, since concentration is what the market discounts here.

Other names that sit close to CTRE: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get CTRE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CTRE sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CTRE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

CTRE is a low-leverage acquisition machine in a demographically favored, politically exposed corner of real estate, so the thesis rests on operators staying solvent through Medicaid funding pressure while management keeps buying at yields well above its cost of capital.

Whether CTRE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CTRE a buy or a sell?, and where the stock could go from here in the CTRE stock forecast.

For income investors, whether CTRE pays a dividend and how the payout looks is covered in does CTRE pay a dividend? And to weigh CTRE against a peer, read the full side-by-side comparisons: CTRE vs OHI and CTRE vs SBRA.